PubRank

E A Padlan

Author PubWeight™ 85.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Conformations of immunoglobulin hypervariable regions. Nature 1990 5.31
2 Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol 1986 4.16
3 The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A 1974 3.92
4 Antibody-antigen complexes. Annu Rev Biochem 1990 3.91
5 Three-dimensional structure of the tryptophan synthase alpha 2 beta 2 multienzyme complex from Salmonella typhimurium. J Biol Chem 1988 3.52
6 Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A 1987 3.48
7 Three-dimensional structure of immunoglobulins. Annu Rev Biochem 1975 1.99
8 Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc Natl Acad Sci U S A 1987 1.82
9 Antibody-antigen complexes. J Biol Chem 1988 1.69
10 Structural basis for the specificity of phosphorylcholine-binding immunoglobulins. Immunochemistry 1976 1.63
11 Structure at 4.5 A resolution of a phosphorylcholine-binding fab. Nat New Biol 1973 1.60
12 Model-building studies of antigen-binding sites: the hapten-binding site of mopc-315. Cold Spring Harb Symp Quant Biol 1977 1.54
13 Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med 1992 1.43
14 Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis. J Mol Biol 1987 1.43
15 Crystals of phosphorylcholine-binding Fab-fragments from mouse myeloma proteins: preparation and x-ray analysis. Proc Natl Acad Sci U S A 1972 1.34
16 Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. J Biol Chem 1985 1.22
17 Structural basis for the specificity of antibody-antigen reactions and structural mechanisms for the diversification of antigen-binding specificities. Q Rev Biophys 1977 1.19
18 H-2Dd exploits a four residue peptide binding motif. J Exp Med 1993 1.13
19 Refined crystal structure of deoxyhemoglobin S. I. Restrained least-squares refinement at 3.0-A resolution. J Biol Chem 1985 1.12
20 A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997 1.10
21 The structural and genetic basis for expression of normal and latent VHa allotypes of the rabbit. Mol Immunol 1984 1.10
22 Variability of three-dimensional structure in immunoglobulins. Proc Natl Acad Sci U S A 1975 1.09
23 On the specificity of antibody/antigen interactions: phosphocholine binding to McPC603 and the correlation of three-dimensional structure and sequence data. Ann Inst Pasteur Immunol 1985 1.08
24 Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Eur J Immunol 2000 1.06
25 Three-dimensional structure of hemoglobin from the polychaete annelid, Glycera dibranchiata, at 2.5 A resolution. J Biol Chem 1974 1.05
26 Crystalline monoclonal antibody Fabs complexed to hen egg white lysozyme. J Mol Biol 1984 0.98
27 An em study of phosphorylcholine-binding fab immunoglobulin fragment crystals. J Ultrastruct Res 1975 0.98
28 Structural implications of sequence variability in immunoglobulins. Proc Natl Acad Sci U S A 1977 0.93
29 Crystal structure of galactan-binding mouse immunoglobulin J539 Fab at 4.5-A resolution. Proc Natl Acad Sci U S A 1979 0.89
30 Structural studies of human autoantibodies. Crystal structure of a thyroid peroxidase autoantibody Fab. J Biol Chem 1996 0.88
31 Immunoglobulin structures at high resolution. Contemp Top Mol Immunol 1975 0.88
32 A monoclonal anti-IgE antibody against an epitope (amino acids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). J Immunol 1988 0.87
33 Structural and genetic basis of idiotypy in the galactan-binding myeloma proteins. Ann Immunol (Paris) 1979 0.87
34 Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors. Proteins 1992 0.87
35 Binding characteristics of IgA 16.4.12E, a monoclonal antibody with specificity for the nonreducing terminal epitope of alpha-(1----6)-dextrans. Comparisons between IgA hybridoma 16.4.12E and myeloma W3129. J Biol Chem 1990 0.87
36 Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol 1999 0.86
37 Evolutionary and structural influences on light chain constant (CL) region of human and mouse immunoglobulins. Proc Natl Acad Sci U S A 1975 0.86
38 Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. EXS 1995 0.85
39 A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int Immunopharmacol 2001 0.85
40 A humanized antibody with specificity for hepatitis B surface antigen. Hum Antibodies Hybridomas 1996 0.84
41 Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995 0.84
42 Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Biochemistry 1998 0.83
43 Twisting into shape. Curr Biol 1992 0.83
44 Evaluation of the structural variation among light chain variable domains. Mol Immunol 1979 0.83
45 Modeling of antibody combining sites. Methods Enzymol 1991 0.82
46 A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution? J Exp Med 1996 0.80
47 A model of the Fc of immunoglobulin E. Mol Immunol 1986 0.80
48 A crystallographic study of deoxy cobalt (II) mesoporphyrin IX myoglobin. J Biol Chem 1975 0.80
49 Identification of the high affinity receptor binding region in human immunoglobulin E. J Biol Chem 1996 0.80
50 Crystalline semisynthetic ribonuclease-S'. Proc Natl Acad Sci U S A 1976 0.79
51 CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 2000 0.79
52 Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Cancer Res 1999 0.79
53 Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol 2001 0.79
54 Localization of rabbit kappa light chain allotypic determinants. Mol Immunol 1986 0.78
55 The nature and importance of the inter-epsilon chain disulfide bonds in human IgE. Eur J Immunol 1991 0.78
56 Glycera dibranchiata hemoglobin. X-ray structure of carbonmonoxide hemoglobin at 1.5 A resolution. J Mol Biol 1994 0.78
57 Quantitation of the immunogenic potential of protein antigens. Mol Immunol 1985 0.77
58 Two Ig framework I epitopic specificities recognized by a rabbit antiserum and a monoclonal antibody to mouse VH chains. J Immunol 1990 0.77
59 Structure of the haemoglobin of the marine annelid worm, Glycera dibranchiata, at 5.5 A resolution. Nature 1968 0.77
60 The X-ray crystal structure of a Valpha2.6Jalpha38 mouse T cell receptor domain at 2.5 A resolution: alternate modes of dimerization and crystal packing. J Mol Biol 1999 0.77
61 Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'. Proteins 1993 0.77
62 Structural significance of sequence variability in antibody complementarity-determining regions. Res Immunol 1994 0.77
63 Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies. J Immunol 1994 0.76
64 Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38. Proc Natl Acad Sci U S A 1994 0.76
65 Why don't humans get scrapie from eating sheep? A possible explanation based on secondary structure predictions. Med Hypotheses 2005 0.76
66 Structure-function studies of an anti-asialo GM1 antibody obtained from a phage display library. J Neuroimmunol 1999 0.76
67 Binding of modified fragments of the Shigella dysenteriae type 1 O-specific polysaccharide to monoclonal IgM 3707 E9 and docking of the immunodeterminant to its modeled Fv. Carbohydr Res 1998 0.76
68 The codon for the methionine at position 129 (M129) in the human prion protein provides an alternative initiation site for translation and renders individuals homozygous for M129 more susceptible to prion disease. Med Hypotheses 2005 0.76
69 Peptide blocking of IgE/receptor interaction: possibilities and pitfalls. Allergy 1997 0.75
70 Commerce versus collaboration. Lancet 1991 0.75
71 Structure of a phosphorycholine-binding mouse myeloma Fab. Transplant Proc 1975 0.75
72 Development of more efficacious antibodies for medical therapy and diagnosis. Prog Nucleic Acid Res Mol Biol 1998 0.75
73 Are humans getting 'mad-cow disease' from eating beef, or something else? Med Hypotheses 2003 0.75
74 The structures of lamprey and bloodworm hemoglobins in relation to their evolution and function. Cold Spring Harb Symp Quant Biol 1972 0.75
75 Antibody Fab assembly: the interface residues between CH1 and CL. Mol Immunol 1986 0.75
76 Does mRNA translation starting from an alternative initiation site contribute to the pathology of Huntington's disease? Med Hypotheses 2000 0.75
77 Structure/function studies on IgE as a basis for the development of rational IgE antagonists. Allergy 1998 0.75
78 Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3. Adv Exp Med Biol 1994 0.75
79 Molecular-replacement structure determination of two different antibody:antigen complexes. Acta Crystallogr B 1990 0.75
80 Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis. Technol Health Care 1998 0.75
81 Protein engineering from plants to animals, from big to small, from outside to inside and other advances. Curr Opin Biotechnol 1997 0.75
82 Humanization of KC4G3, an anti-human carcinoma antibody. Hybridoma 1994 0.75